Markets

Gilead Sciences (GILD) Jumps: Stock Adds 5.8% in Session

Gilead Sciences Inc.GILD was a big mover last session, as the company saw its shares rise almost 6% on the day. The upside was driven by the company's presentation of results from two Phase 3 studies evaluating its investigational once-daily single tablet regimen, Genvoya. This also led to far more shares changing hands than in a normal session. This breaks the recent trend for the company, as the stock is now trading above the volatile price range of $94.80 to $105.49 in the past one-month time frame.

The company has not seen any estimate revision in the past 30 days and its Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Gilead Sciences currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

A better-ranked biomedical stock is Actelion Ltd. ALIOF with a Zacks Rank #1 (Strong Buy).

Is GILD going up? Or down? Predict to see what others think: Up or Down

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

ACTELION LTD (ALIOF): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

GILD

Other Topics

Investing Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More